A myelodysplastic/myeloproliferative neoplasm characterized by the principal involvement of the neutrophil series with leukocytosis and multilineage dysplasia. The neoplastic cells do not have a Phila...
Comprehensive, easy-to-understand information about this condition
How we create this content →The limited documentation surrounding atypical chronic myeloid leukemia is understandable given its rarity. Conditions like aCML affect fewer individuals, which restricts the scope of systematic clinical studies. Additionally, the absence of identified genetic markers complicates efforts to characterize the disease further. This means that ongoing research is crucial to improve understanding and treatment options.
To navigate your care for atypical chronic myeloid leukemia, consider seeking a hematologist with expertise in myelodysplastic and myeloproliferative neoplasms. It is also beneficial to explore clinical trial opportunities, as they may offer access to cutting-edge treatments. Resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide additional information and support. While there are currently no identified patient organizations, connecting with broader cancer support networks may also be helpful.
There are currently 13 active clinical trials investigating various aspects of atypical chronic myeloid leukemia, BCR-ABL1 negative. Notably, ponatinib is an FDA-approved treatment for this condition, while several other orphan drugs are in development, including novel compounds like dasatinib monolauryl sulfate and olverembatinib. For more information on active trials, you can visit [ClinicalTrials.gov](https://clinicaltrials.gov/search?cond=atypical%20chronic%20myeloid%20leukemia%2C%20BCR-ABL1%20negative). This research landscape offers hope for advancements in treatment options.
Actionable guidance for navigating care for atypical chronic myeloid leukemia, BCR-ABL1 negative
To navigate your care for atypical chronic myeloid leukemia, consider seeking a hematologist with expertise in myelodysplastic and myeloproliferative neoplasms. It is also beneficial to explore clinical trial opportunities, as they may offer access to cutting-edge treatments. Resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide additional information and support. While there are currently no identified patient organizations, connecting with broader cancer support networks may also be helpful.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding atypical chronic myeloid leukemia is understandable given its rarity. Conditions like aCML affect fewer individuals, which restricts the scope of systematic clinical studies. Additionally, the absence of identified genetic markers complicates efforts to characterize the disease further. This means that ongoing research is crucial to improve understanding and treatment options.
To navigate your care for atypical chronic myeloid leukemia, consider seeking a hematologist with expertise in myelodysplastic and myeloproliferative neoplasms. It is also beneficial to explore clinical trial opportunities, as they may offer access to cutting-edge treatments. Resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide additional information and support. While there are currently no identified patient organizations, connecting with broader cancer support networks may also be helpful.
There are currently 13 active clinical trials investigating various aspects of atypical chronic myeloid leukemia, BCR-ABL1 negative. Notably, ponatinib is an FDA-approved treatment for this condition, while several other orphan drugs are in development, including novel compounds like dasatinib monolauryl sulfate and olverembatinib. For more information on active trials, you can visit [ClinicalTrials.gov](https://clinicaltrials.gov/search?cond=atypical%20chronic%20myeloid%20leukemia%2C%20BCR-ABL1%20negative). This research landscape offers hope for advancements in treatment options.
Actionable guidance for navigating care for atypical chronic myeloid leukemia, BCR-ABL1 negative
To navigate your care for atypical chronic myeloid leukemia, consider seeking a hematologist with expertise in myelodysplastic and myeloproliferative neoplasms. It is also beneficial to explore clinical trial opportunities, as they may offer access to cutting-edge treatments. Resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide additional information and support. While there are currently no identified patient organizations, connecting with broader cancer support networks may also be helpful.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding atypical chronic myeloid leukemia is understandable given its rarity. Conditions like aCML affect fewer individuals, which restricts the scope of systematic clinical studies. Additionally, the absence of identified genetic markers complicates efforts to characterize the disease further. This means that ongoing research is crucial to improve understanding and treatment options.
To navigate your care for atypical chronic myeloid leukemia, consider seeking a hematologist with expertise in myelodysplastic and myeloproliferative neoplasms. It is also beneficial to explore clinical trial opportunities, as they may offer access to cutting-edge treatments. Resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide additional information and support. While there are currently no identified patient organizations, connecting with broader cancer support networks may also be helpful.
There are currently 13 active clinical trials investigating various aspects of atypical chronic myeloid leukemia, BCR-ABL1 negative. Notably, ponatinib is an FDA-approved treatment for this condition, while several other orphan drugs are in development, including novel compounds like dasatinib monolauryl sulfate and olverembatinib. For more information on active trials, you can visit [ClinicalTrials.gov](https://clinicaltrials.gov/search?cond=atypical%20chronic%20myeloid%20leukemia%2C%20BCR-ABL1%20negative). This research landscape offers hope for advancements in treatment options.
Actionable guidance for navigating care for atypical chronic myeloid leukemia, BCR-ABL1 negative
To navigate your care for atypical chronic myeloid leukemia, consider seeking a hematologist with expertise in myelodysplastic and myeloproliferative neoplasms. It is also beneficial to explore clinical trial opportunities, as they may offer access to cutting-edge treatments. Resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide additional information and support. While there are currently no identified patient organizations, connecting with broader cancer support networks may also be helpful.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.